Veracyte Net Debt vs Total Current Liabilities Analysis

VCYT Stock  USD 41.10  1.51  3.81%   
Veracyte financial indicator trend analysis is much more than just breaking down Veracyte prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Veracyte is a good investment. Please check the relationship between Veracyte Net Debt and its Total Current Liabilities accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.

Net Debt vs Total Current Liabilities

Net Debt vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Veracyte Net Debt account and Total Current Liabilities. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Veracyte's Net Debt and Total Current Liabilities is -0.57. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Veracyte, assuming nothing else is changed. The correlation between historical values of Veracyte's Net Debt and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Veracyte are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Net Debt i.e., Veracyte's Net Debt and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

-0.57
Relationship DirectionNegative 
Relationship StrengthVery Weak

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Total Current Liabilities

Total Current Liabilities is an item on Veracyte balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Veracyte are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from Veracyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Veracyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.At this time, Veracyte's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 392.7 K in 2024, whereas Enterprise Value Multiple is likely to drop (38.14) in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses227.0M236.0M357.9M375.8M
Cost Of Revenue74.4M101.6M112.9M118.5M

Veracyte fundamental ratios Correlations

0.980.981.00.760.96-0.68-0.880.90.610.98-0.490.310.630.970.90.850.280.950.970.990.840.880.730.810.96
0.981.00.970.740.95-0.57-0.850.950.50.98-0.510.20.530.960.890.810.310.960.970.960.870.870.640.80.97
0.981.00.980.730.94-0.57-0.850.960.50.99-0.490.180.530.950.880.80.280.960.970.970.850.880.640.780.97
1.00.970.980.750.96-0.68-0.870.90.610.98-0.480.30.630.970.890.840.260.940.970.990.830.880.730.80.96
0.760.740.730.750.81-0.7-0.730.610.740.7-0.550.50.740.780.770.840.530.660.780.760.860.560.810.840.71
0.960.950.940.960.81-0.71-0.940.850.660.93-0.420.340.680.980.960.90.440.960.930.980.870.880.770.880.96
-0.68-0.57-0.57-0.68-0.7-0.710.69-0.48-0.97-0.530.1-0.7-0.97-0.67-0.77-0.71-0.25-0.61-0.56-0.69-0.52-0.57-0.94-0.74-0.56
-0.88-0.85-0.85-0.87-0.73-0.940.69-0.75-0.65-0.830.25-0.34-0.67-0.94-0.95-0.92-0.5-0.91-0.83-0.94-0.82-0.86-0.75-0.87-0.91
0.90.950.960.90.610.85-0.48-0.750.40.92-0.410.070.420.850.820.680.190.920.910.890.780.850.520.70.91
0.610.50.50.610.740.66-0.97-0.650.40.46-0.170.771.00.630.730.750.330.530.50.630.570.450.980.790.49
0.980.980.990.980.70.93-0.53-0.830.920.46-0.540.180.490.950.830.790.230.930.980.960.830.860.610.740.96
-0.49-0.51-0.49-0.48-0.55-0.420.10.25-0.41-0.17-0.54-0.38-0.2-0.46-0.27-0.48-0.29-0.28-0.56-0.42-0.64-0.06-0.3-0.44-0.37
0.310.20.180.30.50.34-0.7-0.340.070.770.18-0.380.790.340.380.530.330.160.180.320.36-0.030.750.540.14
0.630.530.530.630.740.68-0.97-0.670.421.00.49-0.20.790.650.740.770.330.550.520.650.590.460.990.810.51
0.970.960.950.970.780.98-0.67-0.940.850.630.95-0.460.340.650.950.90.440.960.940.990.890.870.750.870.96
0.90.890.880.890.770.96-0.77-0.950.820.730.83-0.270.380.740.950.880.520.930.850.940.850.860.810.920.91
0.850.810.80.840.840.9-0.71-0.920.680.750.79-0.480.530.770.90.880.490.810.80.890.90.690.860.950.81
0.280.310.280.260.530.44-0.25-0.50.190.330.23-0.290.330.330.440.520.490.320.330.350.620.20.370.590.36
0.950.960.960.940.660.96-0.61-0.910.920.530.93-0.280.160.550.960.930.810.320.90.960.80.950.650.80.97
0.970.970.970.970.780.93-0.56-0.830.910.50.98-0.560.180.520.940.850.80.330.90.950.860.850.630.760.95
0.990.960.970.990.760.98-0.69-0.940.890.630.96-0.420.320.650.990.940.890.350.960.950.850.90.750.840.97
0.840.870.850.830.860.87-0.52-0.820.780.570.83-0.640.360.590.890.850.90.620.80.860.850.650.710.920.84
0.880.870.880.880.560.88-0.57-0.860.850.450.86-0.06-0.030.460.870.860.690.20.950.850.90.650.540.650.94
0.730.640.640.730.810.77-0.94-0.750.520.980.61-0.30.750.990.750.810.860.370.650.630.750.710.540.880.62
0.810.80.780.80.840.88-0.74-0.870.70.790.74-0.440.540.810.870.920.950.590.80.760.840.920.650.880.78
0.960.970.970.960.710.96-0.56-0.910.910.490.96-0.370.140.510.960.910.810.360.970.950.970.840.940.620.78
Click cells to compare fundamentals

Veracyte Account Relationship Matchups

Veracyte fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets275.2M457.2M1.2B1.2B1.1B1.2B
Other Current Liab13.7M10.1M38.8M40.0M36.1M37.9M
Total Current Liabilities17.5M16.8M64.2M62.6M61.2M64.3M
Total Stockholder Equity239.5M421.2M1.1B1.1B1.0B1.1B
Other Liab6.1M8.4M13.1M7.6M8.7M5.6M
Property Plant And Equipment Net17.7M16.8M31.1M30.9M30.9M32.4M
Net Debt(145.7M)(337.0M)(154.3M)(139.5M)(203.8M)(193.6M)
Retained Earnings(246.7M)(281.6M)(357.2M)(393.7M)(468.1M)(444.7M)
Accounts Payable2.3M3.1M12.4M11.9M12.9M13.6M
Cash159.3M349.4M173.2M154.2M216.5M117.7M
Non Current Assets Total87.5M81.5M944.7M907.8M829.3M870.7M
Non Currrent Assets Other2.0M2.0M(35.1M)(26.8M)6.8M7.2M
Other Assets2.0M9.8M2.9M6.2M1.00.95
Cash And Short Term Investments159.3M349.4M173.2M178.9M216.5M119.7M
Net Receivables19.3M18.5M41.5M44.0M40.4M42.4M
Common Stock Total Equity50K58K71K72K82.8K86.9K
Common Stock Shares Outstanding46.1M53.2M67.9M71.5M72.6M41.6M
Liabilities And Stockholders Equity275.2M457.2M1.2B1.2B1.1B1.2B
Non Current Liabilities Total18.3M19.2M27.2M18.6M9.6M17.6M
Inventory6.8M4.7M11.2M14.3M16.1M16.9M
Other Current Assets2.2M3.2M17.2M11.5M12.7M13.3M
Other Stockholder Equity486.1M702.8M1.5B1.5B1.5B1.6B
Total Liab35.8M35.9M91.3M81.2M70.8M44.5M
Property Plant And Equipment Gross17.7M9.0M31.1M30.9M63.7M66.9M
Total Current Assets187.7M375.7M243.1M248.6M285.6M148.7M
Accumulated Other Comprehensive Income(12.0M)0.0(15.1M)(31.3M)(24.0M)(22.8M)
Common Stock50K58K71K72K73K42.9K
Property Plant Equipment8.9M9.0M31.1M30.9M35.5M37.3M
Short Long Term Debt Total13.6M12.3M18.9M14.7M12.6M16.8M
Net Tangible Assets171.7M358.6M185.9M379.3M436.2M458.0M
Long Term Debt25.2M23.9M694K810K931.5K884.9K
Retained Earnings Total Equity(246.7M)(281.6M)(357.2M)(393.7M)(354.3M)(372.1M)
Long Term Debt Total25.2M23.9M694K810K931.5K884.9K
Capital Surpluse486.1M702.8M1.5B1.5B1.7B1.8B
Deferred Long Term Liab4.2M3.9M5.6M4.5M5.2M4.3M
Intangible Assets65.0M59.9M202.7M174.9M88.6M66.2M
Short Term Debt1.4M3.2M8.4M8.1M10.2M7.5M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Veracyte Stock Analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.